Phase 2a trial of Jotrol as treatment for Parkinson’s planned

4 February 2025

The term 'clinical trials' is shown with a handful of oral medications above it and a heart rate graph below it.

Jupiter Neurosciences said it’s planning a Phase 2a clinical trial to test Jotrol, the company’s oral formulation of resveratrol, as a treatment for Parkinson’s disease, in partnership with Zina Biopharmaceuticals.

Zina will assist with aspects of the trial protocol, such as identifying biomarkers and selecting sites for the trial, Jupiter said.

“This partnership with Zina marks a significant milestone for Jupiter as we advance JOTROL into Phase 2 clinical development for Parkinson’s,” Christer Rosén, chairman and CEO of Jupiter, said in a company press release. “Zina’s extensive expertise in trial execution, as well as regulatory, clinical and scientific strategy, will be instrumental in accelerating our development timeline and positioning us for future pivotal studies.”

The trial’s main goal will be to assess the safety of Jotrol in people with Parkinson’s. The trial also will evaluate the pharmacological properties of Jotrol, according to Jupiter. The company didn’t provide specifics about the trial’s planned design or when the study is expected to begin.

Recommended Reading

Column banner for Unshakable Optimist by Mollie Lombardi

There are no rules when it comes to Parkinson’s disease

New formulation as treatment for Parkinson’s

Parkinson’s disease is a neurological disorder marked by the dysfunction and death of brain cells that are responsible for making dopamine, a signaling molecule that helps brain cells communicate with each other and with the rest of the body. Lack of dopamine signaling leads to Parkinson’s symptoms such as movement problems and cognitive issues.

The exact causes of Parkinson’s disease aren’t fully understood, but a growing body of research suggests that abnormal inflammation and oxidative stress, a type of cellular damage, are involved in the disease’s onset and progression.

Resveratrol is a compound found in certain plants, including grapes. It has anti-inflammatory properties as well as antioxidant properties (meaning it can lessen oxidative stress). These properties make it a promising potential Parkinson’s treatment. But its use has been limited because, when high doses are taken orally, it often leads to digestive side effects.

Jotrol is a new formulation of resveratrol containing the compound in a micellar formulation — that is, with the compound dissolved into liquid — that can be taken as an oral capsule. Jupiter is developing Jotrol as a potential treatment for Parkinson’s and other neurological diseases. It was found to improve motor function in a mouse model of Parkinson’s.

The post Phase 2a trial of Jotrol as treatment for Parkinson’s planned appeared first on Parkinson's News Today.

https://parkinsonsnewstoday.com/news/phase-2a-trial-jotrol-treatment-parkinsons-planned/

Parkinsons News Today

Categories

0 Comments

Submit a Comment

Parkinsons, Odd behaviour and Medications

Parkinsons, Odd behaviour and Medications

Do you have a friend or loved one with Parkinsons ? You reckon that would be bad enough ? Is their behaviour a bit (or a lot or even dangerously) out of character? It may be the drugs they are taking and not their real self or the disease!Please read ALL of this post...

Introduction and Excuse me!

Introduction and Excuse me!

Pardon me, while I get this social media enterprise working. It has taken me 12 months to get this far with this editorial labyrinth. My former pre Parkinson’s self would have had this whipped up in a week or two, reality changes ability, however I won’t let it kill...

They Call me Shuffles

They Call me Shuffles

    A diagnosis with Parkinson's changes a lot of things: Motor function, non-motor functions, but maybe even more powerful is the changes in social interactions. I personally don't mind being called "Shuffles" now, I did at first (8 or so years ago I think), I...